An experiment found reduced defensive burying after two protein-derived products. Similarity to diazepam on that task did not establish equivalent clinical anxiolytic efficacy.
The acute test
Rats received a single oral dose of alpha-casein hydrolysate or a fish-protein product, and investigators measured time spent burying a threatening probe. Diazepam served as a comparison treatment.
Both products reduced burying at a tested time point, and the fish-protein product also showed an effect at thirty minutes. The active peptides and proposed gut–brain mechanism remained incompletely understood.
A behavioral comparator has a narrow role
The task measures a particular defensive response after an acute exposure. It does not diagnose an anxiety disorder or assess long-term symptom relief, tolerance, or dependence.
Comparable performance on one endpoint is not a formal demonstration of clinical equivalence or absence of sedation. The study supplies preclinical evidence supporting further investigation. A summary should retain species, product identity, timing, and measured behavior, without presenting a supplement as a proven benzodiazepine replacement or assuming safety of combined use.
Source paper
Original analysis of the supplied journal article, identified as PMC8308885.
Leave a Reply